Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Next Previous
Trial Profile

A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary)
  • Indications Acneiform eruptions; Exanthema; Pruritus; Skin disorders
  • Focus First in man; Pharmacokinetics; Therapeutic Use
  • Acronyms CLEER; CLEER-001
  • Sponsors Hoth Therapeutics

Most Recent Events

  • 05 May 2026 Interim results presented in the Hoth Therapeutics media release.
  • 01 Apr 2026 According to a Hoth Therapeutics media release, building on the positive results, the company has received regulatory approval in Hungary, enabling expansion of the Phase 2 clinical trial into Europe.
  • 24 Mar 2026 Results presented in the Hoth Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top